Bezuclastinib + Sunitinib
Sources
publication, as of 2026-11-07
https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11500
Patients were randomized 1:1 to bezuclastinib 600 mg once daily (QD) + sunitinib 37.5 mg QD (n=204) or sunitinib 37.5 mg QD (n=209) ... mPFS was 16.5 months (95% CI, 13.8-19.2) for the combination vs 9.2 months (95% CI, 7.2-11.0) for monotherapy. ORR significantly improved with the combination vs monotherapy (46% vs 26%
J Clin Oncol 44(16_suppl) abstract 11500 (ASCO 2026), Peak (NCT05208047); congress abstract, preliminary
company_release, as of 2026-11-07
assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026 ... Hypertension (29.4% vs. 27.4%), Neutropenia (15.2% vs. 15.4%), ALT/AST increased (10.8% vs. 1.4%), Anemia (9.3% vs. 4.8%) and Diarrhea (7.8% vs. 7.2%). 7.4% of patients on the bezuclastinib combination and 3.8% of patients on sunitinib monotherapy discontinued study treatment(s) due to treatment related adverse events.
Cogent Biosciences release 05.28.2026
company_release, as of 2026-11-07
Median PFS2 was not reached versus 21 months (HR=0.57, 95% CI: 0.41-0.78)
Cogent Biosciences release, ASCO 2026
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT05208047
A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
ClinicalTrials.gov API v2 record, retrieved 2026-11-07